GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Pacific Edge Ltd (ASX:PEB) » Definitions » 14-Day RSI

Pacific Edge (ASX:PEB) 14-Day RSI : 59.10 (As of Dec. 14, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Pacific Edge 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-12-14), Pacific Edge's 14-Day RSI is 59.10.

The industry rank for Pacific Edge's 14-Day RSI or its related term are showing as below:

ASX:PEB's 14-Day RSI is ranked better than
83.4% of 235 companies
in the Medical Diagnostics & Research industry
Industry Median: 47.06 vs ASX:PEB: 59.10

Competitive Comparison of Pacific Edge's 14-Day RSI

For the Diagnostics & Research subindustry, Pacific Edge's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pacific Edge's 14-Day RSI Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Pacific Edge's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Pacific Edge's 14-Day RSI falls into.



Pacific Edge  (ASX:PEB) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pacific Edge  (ASX:PEB) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Pacific Edge 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Pacific Edge's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Pacific Edge Business Description

Traded in Other Exchanges
Address
87 St David Street, P.O. Box 56, Dunedin, STL, NZL, 9016
Pacific Edge Ltd is a NewZealand based company involved in developing and commercializing diagnostic and prognostic tools for the early detection and management of cancers. It manages and operates the laboratories used for the detection of bladder cancer. The company operates in two segments: Commercial, which includes sales, marketing, laboratory, and support operations to run the commercial businesses world wide; and Research, which is into research and development of diagnostic and prognostic products for human cancer. The commercial segment contributes to the majority of the revenue. Pacific Edge has a product in the marketplace called Cxbladder. Its geographical segments are the United States, New Zealand, and the Rest of the World.